FRMD4B

Across TCGA pan-cancer cohorts, FRMD4B Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated FRMD4B data layer compared with 22 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher FRMD4B Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated FRMD4B expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

UCEC, ACC, and SARC are the cancer types where FRMD4B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	II,III,IV	0.945	0.297	.002	22	view →
ACC	OS	Median	All	0.214	0.802	.002	15	view →
SARC	DFS	Median	All	0.245	0.517	.022	4	view →
SKCM	OS	Median	All	0.580	0.300	.039	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

FRMD4B–UCEC (DFS)

Open the UCEC breakdown →